DEFA14A: Vaxart Aims to Secure Nasdaq Listing with Reverse Stock Split Proposal Amidst Promising Vaccine Developments

Vaxart is seeking stockholder approval for a reverse stock split to maintain its Nasdaq listing while advancing its COVID-19 and norovirus vaccine programs.

Summary

• Vaxart is requesting stockholders to vote in favor of a reverse stock split proposal to maintain its Nasdaq listing.
• The company believes this is crucial to avoid delisting, which could impair liquidity and hinder funding and strategic partnerships.
• Vaxart has made progress with its COVID-19 vaccine candidate, with a government stop work order lifted on April 24, 2025, allowing the Phase 2b trial to continue.
• The company is in active dialogue with BARDA for funding and plans to enroll participants for the 10,000 participant portion of the trial.
• Vaxart is also advancing its norovirus program and expects to report topline data in mid-2025 from a trial with 60 participants.
• Strategic partners are monitoring the norovirus data, which could lead to a partnership and further non-dilutive funding.
• The company has implemented cost reductions to extend its cash runway into 2026 and is seeking additional non-dilutive funding.
• Vaxart will host a Q1 2025 earnings call on May 13, 2025, and a webcast presentation at the Citizens Life Sciences Conference on May 7, 2025, to provide updates.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While there are positive developments in the vaccine programs and cost management, the need for a reverse stock split and reliance on external funding introduce uncertainty.

Positives

• The lifting of the government stop work order on April 24, 2025, allows the COVID-19 vaccine trial to continue and opens the door for further government funding.
• The norovirus program is progressing rapidly, with topline data expected in mid-2025, potentially leading to a strategic partnership and non-dilutive funding.
• Cost reduction measures have extended the cash runway into 2026, providing more time to achieve key milestones.
• Leading independent proxy advisors, Institutional Shareholder Services and Glass Lewis, have recommended stockholders vote FOR the reverse stock split proposal.

Negatives

• Vaxart's stock performance has been disappointing, leading to frustration among some stockholders.
• The company needs to implement a reverse stock split to maintain its Nasdaq listing, indicating potential concerns about its stock price.
• The company's agreement with BARDA requires BARDAs approval of any press release on BARDA-funded projects, and Vaxart does not control the timing of that approval.

Risks

• Failure to obtain stockholder approval for the reverse stock split could result in delisting from Nasdaq.
• Delisting from Nasdaq could impair liquidity, adversely affect the value of securities, and hinder the ability to fund initiatives and explore strategic partnerships.
• The company's reliance on BARDA funding for the COVID-19 vaccine program is subject to BARDA's approval and timing.
• The success of the norovirus program and the potential for a strategic partnership are dependent on positive topline data in mid-2025.
• The company faces challenges within the biotech sector due to macroeconomic disruption.

Future Outlook

Vaxart aims to advance its COVID-19 and norovirus vaccine programs, secure non-dilutive funding, and maintain its Nasdaq listing through a potential reverse stock split. The company plans to deliver on multiple potentially transformative data readouts.

Management Comments

• We would greatly appreciate your voting FOR the reverse stock split proposal to continue our momentum at this critical time.
• We continue to believe Vaxart is a compelling investment opportunity, and we are dedicated to executing on the Companys strategic plan to drive long-term value.

Industry Context

The biotech sector is facing substantial challenges due to macroeconomic disruption, making it crucial for companies like Vaxart to manage costs and secure funding to advance their programs.

Comparison to Industry Standards

• It is difficult to compare Vaxart's results to industry standards without specific financial data or clinical trial results.
• However, the company's focus on oral pill vaccines differentiates it from competitors primarily developing injectable vaccines.
• Companies like Moderna and Pfizer are key competitors in the COVID-19 vaccine space, while others are developing norovirus vaccines using different approaches.

Stakeholder Impact

• Shareholders face potential dilution if a reverse stock split is implemented, but also benefit from the company's efforts to maintain its Nasdaq listing and advance its vaccine programs.
• Employees may be affected by cost reduction measures, including workforce reductions.
• The company's success in developing vaccines could benefit public health and provide value to customers and partners.

Next Steps

• Stockholder vote on the reverse stock split proposal.
• Continued clinical trial of the COVID-19 vaccine candidate.
• Reporting topline data from the norovirus program trial in mid-2025.
• Seeking strategic partnerships and non-dilutive funding.
• Q1 2025 earnings call on May 13, 2025.

Key Dates

Keywords

Vaxart, reverse stock split, Nasdaq, COVID-19 vaccine, norovirus program, BARDA, clinical trial, non-dilutive funding, delisting, stockholders